Refine by
Immune Memory Equipment & Supplies
10 equipment items found
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
After intradermal administration, these modified vesicles deliver both immunostimulatory proteins, which act as adjuvants, and an array of patient-specific tumor-membrane antigens simultaneously to the immune system. This creates robust tumor-specific immunity that Metaclipse anticipates will destroy and/or suppress the growth of metastatic cancer cells. Our ...
Manufactured by:OncoVITA based inParis, FRANCE
Engineered viruses have proven to be powerful “bullets” to target cancer cells and to promote their immunogenic death. Oncolytic viruses are replicative viruses that preferentially infect tumor cells while preserving healthy cells. Some of them, in particular the measles virus, exhibit immuno-adjuvant properties that reinforce the antitumor immune response by breaking immune tolerance ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel immunomodulatory STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery and tolerability. Stimulator of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine ...
Distributed by:Labex Canada Inc. based in, ONTARIO (CANADA)
IgM antibodies provide the first line defense mechanism during viral infections, followed by the adaptive, high affinity, IgG antibodies. IgG antibodies are also important for the long term immunity and for immunological memory. Testing for COVID-19 IgM and IgG antibodies is an effective method for the rapid diagnosis of COVID-19 infection. Detection of COVID-19 ...
Manufactured by:BlueWillow Biologics based inAnn Arbor, MICHIGAN (USA)
Food allergy has become a significant health problem with increasing incidence and severity, particularly in children but continuing throughout adulthood. There is no cure for food allergy, and allergic reactions can be life threatening. According to the Centers for Disease Control, an estimated 8% of children in the U.S. are now affected by food allergies, or roughly 2 students per ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor ...
Manufactured by:ViciniVax BV based inGroningen, NETHERLANDS
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first clinical trial, which has been started in ...